Palvella Therapeutics granted FDA Fast Track Designation to QTORIN

Palvella Therapeutics (PVLA) announced that the FDA has granted Fast Track Designation to QTORIN rapamycin for the treatment of angiokeratomas. “We are thrilled that the FDA has granted Fast Track Designation for QTORIN rapamycin in angiokeratomas,” said Wes Kaupinen, Founder and CEO of Palvella. “Angiokeratomas are chronic, often debilitating lesions with no FDA-approved therapies. This Fast Track designation underscores the potential of QTORIN rapamycin to address this significant unmet need and supports our opportunity to advance what could become the first FDA-approved therapy for these patients. We are committed to working closely with the FDA to advance development with urgency.”